Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. Part 4: Structure-activity relationships for substituents on the quinazoline moiety of 4-[4-(N-substituted(thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 18, 2003, Pages 3001-3004

  Matsuno, Kenji ^a,c   Seishi, Takashi ^a   Nakajima, Takao ^a   Ichimura, Michio ^a   Giese, Neill A ^b   Yu, Jin Chen ^b   Oda, Shoji ^a   Nomoto, Yuji ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c Pharmaceutical Discov Res Labs   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PLATELET DERIVED GROWTH FACTOR RECEPTOR; QUINAZOLINE DERIVATIVE;

ARTICLE; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; INHIBITION KINETICS; PROTEIN PHOSPHORYLATION; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SUBSTITUTION REACTION;

EID: 0041519334     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00634-6     Document Type: Article

References (22)

1. Fretto L.J., Snape A.J., Tomlinson J.E., Seroogy J.J., Wolf D.L., LaRochelle W.J., Giese N.A. J. Biol. Chem. 268:1993;3625.
2. Heldin C.H., Ostman A., Eriksson A., Siegbahn A., Claesson-Welsh L., Westermark B. Kidney Int. 41:1992;571.
3. Ross R., Masuda J., Raines E.W., Gown A.M., Katsuda S., Sasahara M., Malden L.T., Masuko H., Sato H. Science. 248:1990;1009.
4. Wilcox J.N., Smith K.M., Williams L.T., Schwartz S.M., Gordon D. J. Clin. Invest. 82:1988;1134.
5. Gesualdo L., Pinzani M., Floriano J.J., Hassan M.O., Nagy N.U., Schena F.P., Emancipator S.N., Abboud H.E. Lab. Invest. 65:1991;160.
6. Wong L., Yamasaki G., Johnson R.J., Friedman S.L. J. Clin. Invest. 94:1994;1563.
7. Bonner J.C., Lindroos P.M., Rice A.B., Moomaw C.R., Morgan D.L. Am. J. Physiol. Lung Cell Mol. Physiol. 274:1998;L72.
8. Hermanson M., Funa K., Hartman M., Claesson-Welsh L., Heldin C.-H., Westermark B., Nistér M. Cancer Res. 52:1992;3213.
9. Golub T.R., Barker G.F., Lovett M., Gilliland D.G. Cell. 77:1994;307.
10. Matsuno K., Ichimura M., Nakajima T., Tahara K., Fujiwara S., Kase H., Giese N.A., Pandey A., Scarborough R.M., Yu J.-C., Lokker N.A., Irie J., Tsukuda E., Ide S-i., Oda S., Nomoto Y. J. Med. Chem. 45:2002;3057.
11. Matsuno K., Nakajima T., Ichimura M., Giese N.A., Yu J.-C., Lokker N.A., Ide S-i., Oda S., Nomoto Y. J. Med. Chem. 45:2002;4513.
12. Matsuno, K.; Nakajima, T.; Tahara, K.; Seishi, T.; Fujiwara, S.; Ichimura, M.; Giese, N. A.; Yu, J.-C.; Irie, J.; Tsukuda, E.; Ide, S-i.; Oda, S.; Nomoto, Y. 18th Symposium on Medicinal Chemistry, 7th Annual Meeting of Division of Medicinal Chemistry, The Pharmaceutical Society of Japan, Kyoto, Japan, Nov. 25-27, 1998; The Pharmaceutical Society of Japan: Tokyo, 1998; 2P-05.
13. Matsuno, K.; Nakajima, T.; Tahara, K.; Fujiwara, S.; Ichimura, M.; Giese, N. A.; Yu, J.-C.; Irie, J.; Tsukuda, E.; Ide, S-i.; Oda, S.; Nomoto, Y. 217th National Meeting of the American Chemical Society, Anaheim, CA, March 21-25, 1999; American Chemical Society: Washington, DC, 1999; MEDI 61.
14. Yu J.-C., Lokker N., Hollenbach S., Apatira M., Li J., Betz A., Sedlock D., Oda S., Nomoto Y., Matsuno K., Ide S., Tsukuda E., Giese N. J. Pharm. Exp. Ther. 298:2001;1172.
15. Giese N.A., Lokker N.A., Yu J.-C., Matsuno K., Ichimura M., Oda S., Scarborough R.M., Pandey A. Oncol. Spect. 2:2001;550.
16. (a) An example of procedure A: A mixture of 4-chloroquinazoline and excess anhydrous piperazine in 2-propanol was refluxed for 4 h. Evaporation, extraction with chloroform, and condensation with 4-phenoxyphenyl isocyanate in appropriate solvent provided the target molecule 3a. (b) An example of procedure B: A mixture of 2,4-dichloro-6,7-dimethoxyquinazoline and N-tert-butoxycarbonylpiperazine (1.1 equiv) in THF and triethylamine was stirred overnight at room temperature. Evaporation, addition of water and NaCl provided 4-(2-chloro-6,7-dimethoxy-4-quinazolinyl)-1-piperazinecarboxylic acid tert-butyl ester in 98% yield. Removal of Boc group by trifluoroacetic acid in dichloromethane under ice-cooling, and then condensation with 4-phenoxyohenyl isocyanate in DMF and triethylamine provided the target molecule 6c.
17. 1H NMR, Mass and CHN analyses.
18. CHO cells expressing wild-type β-PDGFR was grown to confluency in 96-well microtiter plates under standard tissue culture conditions. Quiescent cells were incubated at 37°C with compound for 30 min followed by the addition of 8 nmol/L PDGF-BB for 10 min. Clarified lysates of cells by centrifugation were transfered into a second microtiter plate in which the wells were previously coated with anti-β-PDGFR mAb, and then incubated for 2 h at room temperature. After washing with binding buffer, rabbit polyclonal anti-phosphotyrosine antibody was added and plates were incubated at 37°C for 60 min. Subsequently, each well was washed with binding buffer and incubated with horse radish peroxidase-conjugated anti-rabbit antibody at 37°C for 60 min. Wells were washed prior to adding 2,2′-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid, and the rate of substrate formation was monitored at 650 nm.
19. Matsuno, K.; Ushiki, J.; Seishi, T.; Ichimura, M.; Giese, N. A.; Yu, J-C.; Takahashi, S.; Oda, S.; Nomoto, Y. J. Med. Chem. In press.
20. Bridges A.J. Chem. Rev. 101:2001;2541. and references cited therein.
21. Rewcastle G.W., Denny W.A., Bridges A.J., Zhou H., Cody D.R., McMichael A., Fry D.W. J. Med. Chem. 38:1995;3482.
22. Bridges A.J., Zhou H., Cody D.R., Rewcastle G.W., McMichael A., Showalter H.D.H., Fry D.W., Kraker A.J., Denny W.A. J. Med. Chem. 39:1996;267.